Drug profile · INN
ceftaroline fosamil
ZINFORO
ceftaroline fosamil (ZINFORO) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — ceftaroline fosamil
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
ceftaroline fosamil (ZINFORO) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ceftaroline fosamil?
ceftaroline fosamil (ZINFORO) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for ceftaroline fosamil?
ZINFORO is a marketed brand name for ceftaroline fosamil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceftaroline fosamil?
ceftaroline fosamil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.